Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly

Blood

Volumn 118, Issue 20, 2011, Pages 5671-5680

  Veerapathran, Anandharaman ^a   Pidala, Joseph ^a   Beato, Francisca ^a   Yu, Xue Zhong ^a   Anasetti, Claudio ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HOMING RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 2; L SELECTIN; MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN BCL 2; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

EID: 81555214616     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-337097     Document Type: Article

References (45)

1. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401-406. (Pubitemid 34875668)
2. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versushost disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399. (Pubitemid 34875667)
3. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med. 2001; 193(11):1311-1318.
4. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499. (Pubitemid 34534513)
5. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004; 104(12):3804-3812. (Pubitemid 39564461)
6. Trenado A, Charlotte F, Fisson S, et al. Recipienttype specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graftversus- host disease while maintaining graftversus- leukemia. J Clin Invest. 2003;112(11): 1688-1696. (Pubitemid 38063726)
7. Gottenberg JE, Lavie F, Abbed K, et al. CD4 CD25(high) regulatory T cells are not impaired in patients with primary Sjogren's syndrome. J Autoimmun. 2005;24(3):235-242. (Pubitemid 40545886)
8. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001; 193(11):1303-1310. (Pubitemid 32524780)
9. Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood. 2001; 98(9):2736-2744.
10. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193(11):1285- 1294.
11. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701-1711. (Pubitemid 44036276)
12. Putnam AL, Brusko TM, Lee MR, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009;58(3):652-662.
13. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203(7):1693- 1700.
14. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GvHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011; 117(14):3921-3928.
15. Hippen KL, Merkel SC, Schirm DK, et al. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versushost disease. Am J Transplant. 2011;11(6):1148- 1157.
16. Masteller EL, Tang Q, Bluestone JA. Antigenspecific regulatory T cells-ex vivo expansion and therapeutic potential. Semin Immunol. 2006; 18(2):103-110. (Pubitemid 43248738)
17. Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA. Expansion of functional endogenous antigen-specific CD4+CD25+regulatory T cells from nonobese diabetic mice. J Immunol. 2005;175(5):3053-3059. (Pubitemid 41170524)
18. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004;199(11):1467-1477. (Pubitemid 38780402)
19. Koenen HJ, Fasse E, Joosten I. CD27/CFSEbased ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J Immunol. 2005;174(12):7573-7583. (Pubitemid 40806261)
20. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 2009;30(5):656-665.
21. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3(83): 83ra42.
22. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol. 1981;126(4):1614- 1619.
23. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 347(1-2):70-78, 2009.
24. Koenen HJ, Fasse E, Joosten I. IL-15 and cognate antigen successfully expand de novo-induced human antigen-specific regulatory CD4+T cells that require antigen-specific activation for suppression. J Immunol. 2003;171(12):6431- 6441.
25. Tang Q, Henriksen KJ, Bi M, et al. In vitroexpanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004; 199(11):1455-1465. (Pubitemid 38780401)
26. Albert MH, Liu Y, Anasetti C, Yu XZ. Antigendependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. Eur J Immunol. 2005;35(9):2598-2607. (Pubitemid 41404043)
27. Yamazaki S, Iyoda T, Tarbell K, et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med. 2003;198(2):235-247. (Pubitemid 37009740)
28. Marguti I, Yamamoto GL, da Costa TB, Rizzo LV, de Moraes LV. Expansion of CD4+ CD25+Foxp3+ T cells by bone marrow-derived dendritic cells. Immunology. 2009;127(1):50-61.
29. Wuest TY, Willette-Brown J, Durum SK, Hurwitz AA. The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells. J Leukoc Biol. 2008;84(4):973-980.
30. Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One. 2009; 4(6):e5994.
31. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood. 2004;104(3):895-903. (Pubitemid 38970590)
32. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708- 712.
33. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272(5258):60-66. (Pubitemid 26110755)
34. Hoffmann P, Eder R, Boeld TJ, et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006; 108(13):4260-4267. (Pubitemid 44913302)
35. Godfrey WR, Spoden DJ, Ge YG, et al. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood. 2005;105(2):750- 758.
36. Nakamura K, Kitani A, Strober W. Cell contactdependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194(5):629-644. (Pubitemid 32844773)
37. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001;166(6): 3789-3796. (Pubitemid 32224903)
38. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762-774. (Pubitemid 39336293)
39. Godfrey WR, Krampf MR, Taylor PA, Blazar BR. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood. 2004;103(3): 1158-1165. (Pubitemid 38129586)
40. Golovina TN, Mikheeva T, Suhoski MM, et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol. 2008;181(4):2855-2868.
41. June CH, Blazar BR. Clinical application of expanded CD4+25+ cells. Semin Immunol. 2006; 18(2):78-88. (Pubitemid 43248735)
42. Dijke IE, Weimar W, Baan CC. Regulatory T cells after organ transplantation: where does their action take place? Hum Immunol. 2008;69(7):389- 398.
43. Sánchez-Fueyo A, Sandner S, Habicht A, et al. Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol. 2006;176(1):329- 334.
44. Semple K, Yu Y, Wang D, Anasetti C, Yu XZ. Efficient and selective prevention of GVHD by antigenspecific induced Tregs via linked-suppression in mice. Biol Blood Marrow Transplant. 2011;17(3): 309-318.
45. Jiang S, Tsang J, Game DS, Stevenson S, Lombardi G, Lechler RI. Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: Potential reagents to promote donor-specific transplantation tolerance. Transplantation. 2006;82(12):1738-1743. (Pubitemid 46035661)